IMM2521

N/A

Report date: 2023/02/13 16:09:28

Base Information

Drug NameIMM2521
Drug Alias NameIMM-2521IMM2521
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Cluster of differentiation 47Programmed death-ligand 1 blockers
TargetsCluster of differentiation 47Programmed death-ligand 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A